Micell Dessolve I Trial Accepted for ACC Cardiovascular Interventions Journal
October 8, 2013 — Micell Technologies Inc. announced that a peer reviewed article discussing imaging and clinical results of the Dessolve I trial of its MiStent Sirolimus-Eluting Absorbable Polymer Coronary Stent System (MiStent SES) was accepted for publication on the JACC Cardiovascular Interventions website. The paper, "First-in-Human Evaluation of a Bioabsorbable Polymer–Coated Sirolimus-Eluting Stent: Imaging and Clinical Results of the Dessolve I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the Native Coronary Arteries)", is planned to also appear in the October 2013 issue of JACC Cardiovascular Interventions.
The article concluded that, upon 18 months' follow-up, the MiStent SES — an absorbable polymer-coated, cobalt chromium, sirolimus-eluting stent — was associated with a low and stable in-stent late lumen loss, complete strut coverage, and no stent thrombosis. Authors of this paper included co-principal investigators for the Dessolve I trial, William Wijns, M.D. and Ph.D., Cardiovascular Center, Aalst, Belgium and John Ormiston, M.B.Ch.B., of the Mercy Angiography Unit, Auckland, New Zealand.
Data included in this paper also will be the subject of a presentation by John Ormiston, M.B.Ch.B. at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco from Oct. 27 to Nov. 1.
For more information: www.interventions.onlinejacc.org, www.micell.com
More like this
- Micell Technologies Receives CE Mark Approval for MiStent SES
- Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES
- Micell Technologies Announces Preliminary Data from DESSOLVE I MiStent DES Study
- Enrollment Completed in DESSOLVE II Study of the MiStent Drug-Eluting Coronary Stent
- First Patient Enrolled in Dissolving Drug-Polymer Coronary Stent Trial